Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21297374 | 1.00 | KISS1R (0.39) | KISS1RCPB2EPHX1 | |
| SCHEMBL16248522 | 0.95 | KISS1R (0.43) | KISS1R | |
| SCHEMBL16692059 | 0.95 | KISS1R (0.43) | KISS1R | |
| SCHEMBL24157441 | 0.87 | KISS1R (0.47) | KISS1RCPB2EPHX1 | |
| SCHEMBL27309897 | 0.86 | KISS1R (0.39) | KISS1RCPB2EPHX1 | |
| SCHEMBL17662433 | 0.86 | KDM4E (0.35) | — | |
| SCHEMBL21891783 | 0.86 | — | — | |
| SCHEMBL16248631 | 0.86 | KDM4E (0.35) | — | |
| SCHEMBL11956479 | 0.86 | KDM4E (0.35) | — | |
| SCHEMBL13468552 | 0.85 | KISS1R (0.41) | KISS1RCPB2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20220023290-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-01-27 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023290-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, DCLRE1A | KISS1R 2367/4885CPB2 3863/4885EPHX1 4062/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | KISS1R 1161/4885CPB2 910/4885EPHX1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.